News from nektar therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 13, 2019, 06:45 ET First-in-Human Data Presented from Phase 1a Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology

Nektar Therapeutics (Nasdaq: NKTR) today announced the results of the first-in-human Phase 1a study evaluating single-ascending doses of NKTR-358, a...


Jun 11, 2019, 09:00 ET Nektar Therapeutics to Host Webcast Conference Call with Immunology Expert for Analysts & Investors During 2019 European Congress of Rheumatology (EULAR 2019)

Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with an immunology expert and company...


Jun 01, 2019, 09:00 ET Nektar Therapeutics Presents Biomarker and Clinical Data from PIVOT-02 Phase 2 Study of Bempegaldesleukin with Nivolumab at 2019 ASCO Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) announced today that biomarker and clinical data from PIVOT-02 is being presented at the 2019 American Society of...


May 23, 2019, 08:00 ET Nektar Announces the Launch of Inheris Biopharma, Inc.

Nektar Therapeutics (Nasdaq: NKTR) today announced the formation of Inheris Biopharma, Inc., a wholly-owned subsidiary of Nektar and a CNS-focused...


May 15, 2019, 17:00 ET Nektar Therapeutics Announces Five Accepted Abstracts at 2019 American Society of Clinical Oncology's (ASCO) Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced five abstracts accepted for presentation at the 55th Annual Meeting of the American Society of...


May 08, 2019, 16:10 ET Nektar Therapeutics Reports Financial Results for the First Quarter of 2019

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2019. Cash and investments in...


May 01, 2019, 17:00 ET Nektar to Announce Financial Results for the First Quarter 2019 on Wednesday, May 8, 2019, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2019 on Wednesday, May 8, 2019, after the close of...


Apr 02, 2019, 15:00 ET Nektar Therapeutics Presents Preclinical Data on its Immuno-Oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019

Nektar Therapeutics (Nasdaq: NKTR) today presented preclinical data on its immuno-oncology pipeline candidates, bempegaldesleukin (NKTR-214 or...


Apr 01, 2019, 16:15 ET Vaccibody AS and Nektar Therapeutics Present New Preclinical Data from their Immuno-Oncology Collaboration at the American Association for Cancer Research (AACR) Annual Meeting 2019

Vaccibody AS and Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of new preclinical data for VB10.NEO, a personalized neoantigen...


Mar 06, 2019, 16:30 ET Nektar Therapeutics to Webcast Presentation at the Cowen and Company 39th Annual Health Care Conference

Nektar Therapeutics (Nasdaq: NKTR) today announced that its Chief Scientific Officer, Jonathan Zalevsky, Ph.D., is scheduled to present at the Cowen...


Mar 01, 2019, 16:40 ET Nektar Therapeutics Presents Preliminary Immune Activation, Safety and Clinical Activity Data from the Ongoing Dose-Escalation Stage of the REVEAL Study at 2019 ASCO-SITC Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced early results from the ongoing dose-escalation stage of the first-in-human REVEAL Phase 1/2...


Feb 28, 2019, 16:10 ET Nektar Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2018. Cash and...


Feb 27, 2019, 16:35 ET Nektar Therapeutics Announces Several Preclinical Data Presentations for its Immuno-oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019

Nektar Therapeutics (Nasdaq: NKTR) today announced several preclinical data presentations for its immuno-oncology pipeline candidates,...


Feb 25, 2019, 17:00 ET Nektar Therapeutics to Webcast Conference Call for Analysts and Investors at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Nektar Therapeutics (Nasdaq: NKTR) announced today that it will webcast an analyst and investor conference call with lead investigator of the REVEAL...


Feb 21, 2019, 16:30 ET Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2018 on Thursday, February 28, 2019, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2018, on Thursday, February ...


Feb 15, 2019, 15:15 ET Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Metastatic Urothelial Carcinoma Patients at the 2019 ASCO Genitourinary Cancers Symposium

Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation of new clinical data for bempegaldesleukin1 (NKTR-214) in combination with...


Feb 11, 2019, 17:14 ET Nektar Therapeutics to Webcast Conference Call with Urothelial Cancer Specialist for Analysts & Investors at the 2019 ASCO Genitourinary Cancers Symposium

Nektar Therapeutics (Nasdaq: NKTR) announced today that it will webcast an analyst and investor conference call with a urothelial cancer specialist...


Dec 27, 2018, 08:30 ET Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA

Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 37th Annual J.P....


Nov 14, 2018, 09:00 ET Nektar Appoints Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs

Nektar Therapeutics (Nasdaq: NKTR) today announced the appointment of Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of...


Nov 09, 2018, 18:15 ET Nektar Therapeutics Presents New Clinical and Preclinical Data for its Immuno-Oncology Pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation of new clinical and preclinical data for its I-O pipeline at the 2018 Society for...


Nov 07, 2018, 16:10 ET Nektar Therapeutics Reports Financial Results for the Third Quarter of 2018

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2018. Cash and investments in...


Nov 06, 2018, 08:30 ET New Clinical Oncology Collaboration Between Nektar and Pfizer to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers

Nektar Therapeutics (NASDAQ:NKTR) announced that it has entered into an oncology clinical collaboration with Pfizer Inc. (NYSE:PFE) to evaluate...


Nov 06, 2018, 08:00 ET Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialists for Analysts & Investors During 2018 Society for Immunotherapy of Cancer 33rd Annual Meeting

Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with melanoma specialists and company...


Oct 30, 2018, 17:00 ET Nektar to Announce Financial Results for the Third Quarter 2018 on Wednesday, November 7, 2018, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Wednesday, November 7, 2018, after the close of...


Oct 02, 2018, 08:00 ET Nektar Therapeutics Announces Ten Abstracts Accepted for Presentation at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced that ten clinical and preclinical data presentations across its immuno-oncology portfolio will be...